Since its inception in 2004, NeurAxon has been dedicated to developing novel pain therapeutics targeting neuronal nitric oxide synthase (nNOS). The Company has issued and pending composition of matter patents on selective small molecule inhibitors of nNOS. The focus of the Company's efforts is to continue to build upon this intellectual property asset and leverage it with product focused medicinal chemistry, biology and clinical development expertise to create a pipeline of proprietary single and dual-action small molecule nNOS inhibitors for migraine and other pain indications. NeurAxon's research operations are located in Ontario.
Board of Directors
Scientific Advisory Board